Drug delivery

InSitu Biologics Shares Latest Investigational Work at ASRA Meeting

Retrieved on: 
Thursday, November 17, 2022
Professional Services, Research, Science, Veterinary, Practice Management, Alternative Energy, Radiology, Energy, Nanotechnology, Pharmaceutical, Optical, Oncology, Infectious Diseases, Other Consumer, Software, Genetics, Defense, Clinical Trials, Hardware, Biotechnology, Data Management, AIDS, Technology, Health, Legal, Insurance, Consumer, Finance, Construction & Property, Sale, Drug delivery, Insitu, Pain management, Innovation, Pharmacokinetics, Cancer, Twilight anesthesia, Society, Inflammation, Pain, Geography, Local anesthetic, Infection, Medical device, Pharmaceutical industry

InSitu Biologics, Inc. will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine Meeting of the American Society of Regional Anesthesia on November 18th, 2022.

Key Points: 
  • InSitu Biologics, Inc. will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine Meeting of the American Society of Regional Anesthesia on November 18th, 2022.
  • This scientific report will highlight the Companys work on multiple drug formulations within the multi-phase drug delivery matrix, demonstrating its ability to tune the matrix formulations drug-loading and prolonged-delivery characteristics.
  • InSitu Biologics: InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery platform for localized treatment of pain, cancer, and infection.
  • InSitu Biologics is currently conducting investigational pre-clinical work.

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Retrieved on: 
Tuesday, November 22, 2022
Health, Platform, RPT, Immunotherapy, Drug delivery, Therapy, Liver, Liver disease, Partnership, FDA, Pancreas, Patient, Uveal melanoma, Immune system, PET, CD8, Phase II, Medical imaging, Pharmaceutical industry

Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.

Key Points: 
  • Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.
  • Our agreement with TriSalus highlights our expanding partnership network and showcases the increasing adoption of our CD8 ImmunoPET technology."
  • CD8 ImmunoPET is an 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.
  • TriSalusLife Sciences is anoncology therapeutics company integrating immunotherapy withdisruptivedelivery technology to transform the treatment paradigm for patients with liver andpancreatictumors.

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Retrieved on: 
Tuesday, November 22, 2022
Health, Platform, RPT, Immunotherapy, Drug delivery, Therapy, Liver, Liver disease, Partnership, FDA, Pancreas, Patient, Uveal melanoma, Immune system, PET, CD8, Phase II, Medical imaging, Pharmaceutical industry

Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.

Key Points: 
  • Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.
  • Our agreement with TriSalus highlights our expanding partnership network and showcases the increasing adoption of our CD8 ImmunoPET technology."
  • CD8 ImmunoPET is an 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.
  • TriSalusLife Sciences is anoncology therapeutics company integrating immunotherapy withdisruptivedelivery technology to transform the treatment paradigm for patients with liver andpancreatictumors.

Technology Growth Opportunities for Exosome-Mediated Drug Delivery, 2022 Market Research Study - Increasing R&D Collaborations and Emerging Therapeutic Pipelines - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Health, Pharmaceutical, Exosome, Seminal vesicles, Investment, Drug delivery, RNA, Therapy, Cancer, Adoption, Technology, Technology transfer, Research, Degenerative disease, Nanomedicine, CRISPR, Vaccine, RNA transfection, Safety, Biotechnology, MicroRNA, COVID-19, Efficiency, Pharmaceutical industry

The "Technology Growth Opportunities for Exosome-Mediated Drug Delivery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Technology Growth Opportunities for Exosome-Mediated Drug Delivery" report has been added to ResearchAndMarkets.com's offering.
  • This research provides an overview of the emerging modalities delivered by exosomes in the preclinical or clinical stages, highlighting technological roadmaps, market trends, and the latest research findings.
  • This study rounds up the analysis with growth opportunities for the clinical translation of exosome nanocarriers.
  • The United States has become the hub of the exosome-mediated drug delivery industry, with many private and academic institutions conducting research and technology adoption.

Nanopharmaceuticals Global Market Report 2022: Huge Market Potential in Pharmaceutical Companies for Development of Effective Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Pharmaceutical, Health, Infection, Value, CHF, Drug delivery, Neurology, Acquisition, Market share analysis, Growth, CAGR, Business Growth Fund, GBP, CAD, Use, JPY, Strategic management, Research, Incidence, AUD, Degenerative disease, SM-102, Application, Liposome, Decision-making, USD, Customer support, Retail, EUR, Oncology

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.

Key Points: 
  • The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.
  • Based on Application, the market was studied across Anti-infective, Anti-inflammatory, Drug Delivery, Neurology, and Oncology.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Microfluidics Global Market Report 2022: Rising Demand for Advanced and Better Point-Of-Care Testing Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Health, Medical Devices, Journal of Veterinary Diagnostic Investigation, Growth, Acquisition, TE Connectivity, IVD, TE, Drug delivery, Point-of-care testing, Polymer, Medication, Silicon, POCT, American Rescue Plan Act of 2021, Glass, Wi, Inc., Microfluidics, POC, HHS, Fine chemical

The main types of microfluidics include silicone-based microfluidics, glass-based microfluidics, and polymer-based microfluidics.

Key Points: 
  • The main types of microfluidics include silicone-based microfluidics, glass-based microfluidics, and polymer-based microfluidics.
  • The regions covered in the microfluidics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The rising demand for advanced and better point-of-care testing in the healthcare industry is driving the microfluidics market.
  • Therefore, the rising demand for point-of-care testing is expected to boost demand for microfluidics during the forecast period.

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Retrieved on: 
Thursday, October 20, 2022
Quality of life, CA, Parenteral Drug Association, NYSE, Biotechnology, Patient, Program, Ketamine, Group, PDA, Opioid, Stevanato Group, Drug delivery, Biomedicine, Solution, Engineering, Leadership, Fine chemical, Pharmaceutical industry

SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.

Key Points: 
  • SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.
  • This award recognizes the collaboration between Bexson Biomedical and Stevanato Group to optimize Stevanato Group's innovative wearable device On Body Delivery System (OBDS) with Bexson's formulation technology.
  • "It is an honor for Stevanato Group to receive this award, which recognizes the long collaboration with Bexson," adds Stevanato Group's, Paolo Golfetto.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Global Vietnam Generic Drugs Market Report 2022: Quickly Developing National Pharmaceutical Industry Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, Pharmaceutical, Molecule, Mode, Drug delivery, Drug, Name, Prescription, Application, Growth, Market share, Diabetes, Route of administration, Oral, Cardiovascular disease, Form, Conditional sentence, Pharmaceutical industry

Vietnam generic drugs market is projected to witness growth at a significant rate during the forecast period, 2023-2027.

Key Points: 
  • Vietnam generic drugs market is projected to witness growth at a significant rate during the forecast period, 2023-2027.
  • The market growth can be attributed to the rising demand for affordable drugs and the growing need for over-the-counter drugs against branded drugs.
  • One of the main factors boosting the growth of the Vietnam generic drugs market in the coming five years is the nation's quickly developing pharmaceutical industry.
  • In this report, Vietnam generic drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    Vietnam Generic Drugs Market, By Mode of Drug Delivery:

PDA Announces Nearly 100 Exhibitors at the 19th Universe of Pre-Filled Syringes and Injection Devices Conference

Retrieved on: 
Thursday, September 29, 2022
Universe, PDA, Drug delivery, Exhibition, Parenteral Drug Association, University residence hall network, Industry, Syringe, Patient, Organization, Technology, ANSI, Rise Up (conference), Science, UPS, Conference, Education, EMA, Pharmaceutical industry, EU

BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019. It will be held in Palm Springs, Ca., 18-19 Oct. The 2020 and 2021 conferences were held as virtual events.

Key Points: 
  • BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019.
  • "The organizing committee is delighted to welcome delegates back to the PDA Universe of Pre-Filled Syringes and Injection Devices Conference," said Mathias Romacker, committee co-chair and executive advisor, Kymanox.
  • "This year we are finally back to meet in person and so many new topics are there to be discussed.
  • Continued advances in materials of construction, manufacturing processes, injection processes and safety devices, and other technology improvements create a dynamic environment in the drug delivery device arena.

India Generic Drugs Market Research Report 2022: Small Molecule Generics v/s Biosimilars - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Health, Pharmaceutical, Molecule, Cardiovascular disease, Mode, Bolt-on acquisition, Diabetes, Form, Patient, Conditional sentence, Forecast, Application, Oral, Prevalence, Technology, USD, CAGR, Market share, Competition, Awareness, Route of administration, Drug delivery, Generic drug, Medical device, Health insurance

In developing countries like India, government bodies and other regulatory bodies have encouraged manufacturers to launch effective generic drugs supporting market growth.

Key Points: 
  • In developing countries like India, government bodies and other regulatory bodies have encouraged manufacturers to launch effective generic drugs supporting market growth.
  • To analyze the historical growth of the market size of the Indian Generic Drugs Market from 2018 to 2021.
  • To estimate and forecast the market size of the Indian Generic Drugs Market from 2023 to 2028 and growth rate until 2028.
  • To identify key sustainable strategies adopted by the market players in the Indian Generic Drugs Market.